Midkine is expressed by infiltrating macrophages in in-stent restenosis in hypercholesterolemic rabbits

Journal of Vascular Surgery

Volumn 47, Issue 6, 2008, Pages 1322-1329

  Narita, Hiroshi ^a   Chen, Sen ^a   Komori, Kimihiro ^a   Kadomatsu, Kenji ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIDKINE; OXIDIZED LOW DENSITY LIPOPROTEIN; THIOGLYCOLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL REACTIVITY; CELL DIFFERENTIATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; INTIMA; MACROPHAGE; NONHUMAN; PATHOGENESIS; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; RESTENOSIS;

ANGIOPLASTY, BALLOON; ANIMALS; ATHEROSCLEROSIS; CELL DIFFERENTIATION; CELL LINE; CELL MOVEMENT; CELLS, CULTURED; CHOLESTEROL, DIETARY; CONSTRICTION, PATHOLOGIC; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; HYPERCHOLESTEROLEMIA; HYPERPLASIA; ILIAC ARTERY; LIPOPROTEINS, LDL; MACROPHAGES; MALE; METALS; MICE; PROSTHESIS DESIGN; RABBITS; STENTS; TIME FACTORS; UP-REGULATION;

EID: 44349123083     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2007.12.037     Document Type: Article

References (43)

1. Fattori R., and Piva T. Drug-eluting stents in vascular intervention. Lancet 361 (2003) 247-249
2. Dormandy J.A., and Rutherford R.B. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 31 (2000) S1-S296
3. Babapulle M.N., Joseph L., Belisle P., Brophy J.M., and Eisenberg M.J. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 364 (2004) 583-591
4. Nakatani M., Takeyama Y., Shibata M., Yorozuya M., Suzuki H., Koba S., et al. Mechanisms of restenosis after coronary intervention: difference between plain old balloon angioplasty and stenting. Cardiovasc Pathol 12 (2003) 40-48
5. Schwartz S.M., deBlois D., and O'Brien E.R. The intima. Soil for atherosclerosis and restenosis. Circ Res 77 (1995) 445-465
6. Moreno P.R., Palacios I.F., Leon M.N., Rhodes J., Fuster V., and Fallon J.T. Histopathologic comparison of human coronary in-stent and post-balloon angioplasty restenotic tissue. Am J Cardiol 84 (1999) 462-466 A9
7. Horvath C., Welt F.G., Nedelman M., Rao P., and Rogers C. Targeting CCR2 or CD18 inhibits experimental in-stent restenosis in primates: inhibitory potential depends on type of injury and leukocytes targeted. Circ Res 90 (2002) 488-494
8. Kawamoto R., Yamashita A., Nishihira K., Furukoji E., Hatakeyama K., Ishikawa T., et al. Different inflammatory response and oxidative stress in neointimal hyperplasia after balloon angioplasty and stent implantation in cholesterol-fed rabbits. Pathol Res Pract 202 (2006) 447-456
9. Schwartz R.S., Edelman E.R., Carter A., Chronos N., Rogers C., Robinson K.A., et al. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation 106 (2002) 1867-1873
10. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362 (1993) 801-809
11. Kodama T., Freeman M., Rohrer L., Zabrecky J., Matsudaira P., and Krieger M. Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils. Nature 343 (1990) 531-535
12. Deuel T.F., Zhang N., Yeh H.J., Silos-Santiago I., and Wang Z.Y. Pleiotrophin: a cytokine with diverse functions and a novel signaling pathway. Arch Biochem Biophys 397 (2002) 162-171
13. Kurtz A., Schulte A.M., and Wellstein A. Pleiotrophin and midkine in normal development and tumor biology. Crit Rev Oncog 6 (1995) 151-177
14. Muramatsu T. Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J Biochem (Tokyo) 132 (2002) 359-371
15. Rauvala H., Huttunen H.J., Fages C., Kaksonen M., Kinnunen T., Imai S., et al. Heparin-binding proteins HB-GAM (pleiotrophin) and amphoterin in the regulation of cell motility. Matrix Biol 19 (2000) 377-387
16. Sato W., Kadomatsu K., Yuzawa Y., Muramatsu H., Hotta N., Matsuo S., et al. Midkine is involved in neutrophil infiltration into the tubulointerstitium in ischemic renal injury. J Immunol 167 (2001) 3463-3469
17. Kawai H., Sato W., Yuzawa Y., Kosugi T., Matsuo S., Takei Y., et al. Lack of the growth factor midkine enhances survival against cisplatin-induced renal damage. Am J Pathol 165 (2004) 1603-1612
18. Maruyama K., Muramatsu H., Ishiguro N., and Muramatsu T. Midkine, a heparin-binding growth factor, is fundamentally involved in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 50 (2004) 1420-1429
19. Sato W., Takei Y., Yuzawa Y., Matsuo S., Kadomatsu K., and Muramatsu T. Midkine antisense oligodeoxyribonucleotide inhibits renal damage induced by ischemic reperfusion. Kidney Int 67 (2005) 1330-1339
20. Horiba M., Kadomatsu K., Nakamura E., Muramatsu H., Ikematsu S., Sakuma S., et al. Neointima formation in a restenosis model is suppressed in midkine-deficient mice. J Clin Invest 105 (2000) 489-495
21. Hayashi K., Banno H., Kadomatsu K., Takei Y., Komori K., and Muramatsu T. Antisense oligodeoxyribonucleotide as to the growth factor midkine suppresses neointima formation induced by balloon injury. Am J Physiol Heart Circ Physiol 288 (2005) H2203-H2209
22. Banno H., Takei Y., Muramatsu T., Komori K., and Kadomatsu K. Controlled release of small interfering RNA targeting midkine attenuates intimal hyperplasia in vein grafts. J Vasc Surg 44 (2006) 633-641
23. Maeda M., Yamamoto I., Fujio Y., and Azuma J. Homocysteine induces vascular endothelial growth factor expression in differentiated THP-1 macrophages. Biochim Biophys Acta 1623 (2003) 41-46
24. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135-1143
25. Schwartz S.M., Virmani R., and Rosenfeld M.E. The good smooth muscle cells in atherosclerosis. Curr Atheroscler Rep 2 (2000) 422-429
26. Takada T., Toriyama K., Muramatsu H., Song X.J., Torii S., and Muramatsu T. Midkine, a retinoic acid-inducible heparin-binding cytokine in inflammatory responses: chemotactic activity to neutrophils and association with inflammatory synovitis. J Biochem (Tokyo) 122 (1997) 453-458
27. Inoh K., Muramatsu H., Ochiai K., Torii S., and Muramatsu T. Midkine, a heparin-binding cytokine, plays key roles in intraperitoneal adhesions. Biochem Biophys Res Commun 317 (2004) 108-113
28. Kosugi T., Yuzawa Y., Sato W., Arata-Kawai H., Suzuki N., Kato N., et al. Midkine is involved in tubulointerstitial inflammation associated with diabetic nephropathy. Lab Invest 87 (2007) 903-913
29. Mangi A.A., and Dzau V.J. Gene therapy for human bypass grafts. Ann Med 33 (2001) 153-155
30. Mann M.J., Whittemore A.D., Donaldson M.C., Belkin M., Conte M.S., Polak J.F., et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet 354 (1999) 1493-1498
31. Li Y., Fukuda N., Kunimoto S., Yokoyama S., Hagikura K., Kawano T., et al. Stent-based delivery of antisense oligodeoxynucleotides targeted to the PDGF A-chain decreases in-stent restenosis of the coronary artery. J Cardiovasc Pharmacol 48 (2006) 184-190
32. Feldman L.J., Aguirre L., Ziol M., Bridou J.P., Nevo N., Michel J.B., et al. Interleukin-10 inhibits intimal hyperplasia after angioplasty or stent implantation in hypercholesterolemic rabbits. Circulation 101 (2000) 908-916
33. Rogers C., Edelman E.R., and Simon D.I. A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc Natl Acad Sci U S A 95 (1998) 10134-10139
34. Joner M., Farb A., Cheng Q., Finn A.V., Acampado E., Burke A.P., et al. Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-beta and MCP-1. Arterioscler Thromb Vasc Biol 27 (2007) 182-189
35. Hayashi K., Kadomatsu K., and Muramatsu T. Requirement of chondroitin sulfate/dermatan sulfate recognition in midkine-dependent migration of macrophages. Glycoconj J 18 (2001) 401-406
36. Maeda N., Ichihara-Tanaka K., Kimura T., Kadomatsu K., Muramatsu T., and Noda M. A receptor-like protein-tyrosine phosphatase PTPzeta/RPTPbeta binds a heparin-binding growth factor midkine. Involvement of arginine 78 of midkine in the high affinity binding to PTPzeta. J Biol Chem 274 (1999) 12474-12479
37. Qi M., Ikematsu S., Maeda N., Ichihara-Tanaka K., Sakuma S., Noda M., et al. Haptotactic migration induced by midkine. Involvement of protein-tyrosine phosphatase zeta. Mitogen-activated protein kinase, and phosphatidylinositol 3-kinase. J Biol Chem 276 (2001) 15868-15875
38. Banai S., Wolf Y., Golomb G., Pearle A., Waltenberger J., Fishbein I., et al. PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine. Circulation 97 (1998) 1960-1969
39. Ferns G.A., Raines E.W., Sprugel K.H., Motani A.S., Reidy M.A., and Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 253 (1991) 1129-1132
40. Nabel E.G., Yang Z., Liptay S., San H., Gordon D., Haudenschild C.C., et al. Recombinant platelet-derived growth factor B gene expression in porcine arteries induce intimal hyperplasia in vivo. J Clin Invest 91 (1993) 1822-1829
41. Boucher P., Gotthardt M., Li W.P., Anderson R.G., and Herz J. LRP: role in vascular wall integrity and protection from atherosclerosis. Science 300 (2003) 329-332
42. Muramatsu H., Zou K., Sakaguchi N., Ikematsu S., Sakuma S., and Muramatsu T. LDL receptor-related protein as a component of the midkine receptor. Biochem Biophys Res Commun 270 (2000) 936-941
43. Shibata Y., Muramatsu T., Hirai M., Inui T., Kimura T., Saito H., et al. Nuclear targeting by the growth factor midkine. Mol Cell Biol 22 (2002) 6788-6796